Recurrent Squamous Cell Carcinoma of the Hypopharynx Completed Phase 2 Trials for Capecitabine (DB01101)

IndicationStatusPhase
DBCOND0029504 (Recurrent Squamous Cell Carcinoma of the Hypopharynx)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01044433Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and NeckTreatment